The Biomarker Bottleneck in Immuno-oncology: Understanding to Overcome

The Scientist is bringing together a panel of experts to discuss their research and provide insight into how this issue is being overcome.

Oct 29, 2018
The Scientist Creative Services Team

The Biomarker Bottleneck in Immuno-oncology: Understanding to Overcome from thescientistllc on Vimeo.

In recent years, an avalanche of new compounds has been developed for the treatment of cancer with immunotherapy. However, novel biomarkers are required to guide treatment with these new compounds. The complexity of cancer and the immune response means predictive biomarkers for immuno-oncology can differ vastly between people and cancer subtypes. New approaches for biomarker discovery include using next-generation gene expression profiling, which allows patient-level biomarker determination, as well as multiplex spatial protein profiling,  to identify protein targets including immune cell markers and checkpoint proteins. To delve deeper into the biomarker bottleneck, The Scientist is bringing together a panel of experts to discuss their research and provide insight into how this issue is being overcome.

Topics to be covered:

  • Assessing heterogeneity of immune cell infiltration in tumors to predict response to cancer immunotherapy
  • Mapping the landscape of tumors

Meet the Speakers:

Alice O. Kamphorst, PhD
Assistant Professor, Department of Oncological Sciences
Precision Immunology Institute
Icahn School of Medicine at Mount Sinai

Evisa Gjini, PhD
Associate Director, Department of Pathology
Brigham and Women's Hospital
Dana Farber Cancer Institute